ebola
viru
ebov
diseas
caus
seriou
recurr
epidem
recent
year
result
fatal
rate
nearli
effect
experiment
therapi
ebov
use
monoclon
antibodi
mab
work
describ
develop
cell
engin
transient
stabl
express
neutral
antiebov
monoclon
antibodi
transfect
cell
tricistron
vector
produc
heavi
light
chain
antibodi
intracellular
green
fluoresc
protein
gfp
use
lipofectamin
select
transfect
cell
use
puromycin
pressur
dilut
clone
clone
disk
integr
strategi
gener
mabproduc
cell
day
transient
express
mgl
stabl
pool
produc
week
express
level
mgl
stabl
clone
express
level
mgl
obtain
within
week
produc
antibodi
exhibit
expect
function
recogn
gp
glycoprotein
ebola
viru
elisa
assay
cell
bind
experi
biorxiv
preprint
use
cell
engin
express
ebov
gp
membran
surfac
combin
use
gfp
set
select
techniqu
describ
drastic
reduc
time
transfect
stabl
clone
gener
without
resort
costli
equip
outbreak
emerg
platform
significantli
shorten
develop
new
biopharmaceut
vaccin
two
major
ebola
viru
ebov
outbreak
occur
sinc
result
case
death
diseas
caus
ebov
exhibit
fatal
rate
nearli
valu
encount
region
current
approv
treatment
vaccin
exist
ebov
standard
care
recommend
ebov
patient
consist
mainli
use
analges
antiinflammatori
drug
antibiot
antiemet
antihypertens
antiepilept
drug
pharmaceut
compani
research
group
continu
effort
develop
potenti
prevent
therapeut
antiebov
compound
run
clinic
trial
present
promis
altern
specif
ebov
treatment
monoclon
antibodi
mab
therapi
base
mab
cocktail
ie
zmapp
remdesivir
current
clinic
trial
mechan
action
cocktail
simpl
specif
mab
recogn
bind
ebov
therebi
interf
viru
replic
inhibit
neutral
infect
ebov
gp
glycoprotein
main
affin
target
antiebov
mab
differ
mab
bind
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
differ
gp
region
aim
use
antibodi
mixtur
target
viru
differ
site
first
cocktail
use
human
studi
far
zmapp
compos
three
murin
chimer
antibodi
recent
host
consid
experiment
product
antiebov
antibodi
includ
cattl
equin
chines
hamster
ovari
cho
cell
among
altern
mammalian
cell
obviou
attract
choic
product
antiebov
mab
mammalian
cell
produc
complex
larg
glycoprotein
gener
glycosyl
pattern
close
resembl
induc
viral
infect
human
cell
mammalian
cell
line
use
frequent
biopharmaceut
industri
produc
protein
therapeut
cho
cell
line
among
human
origin
therefor
offer
advantag
gener
human
glycosyl
pattern
cell
line
establish
primari
embryon
human
kidney
transform
human
adenoviru
type
dna
common
cell
line
use
produc
recombin
protein
second
cho
cell
line
hek
cell
use
express
tool
year
eas
cultur
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
year
mani
strategi
propos
experiment
demonstr
acceler
process
gener
stabl
clone
capabl
produc
reason
good
quantiti
pharmaceut
compound
test
studi
combin
differ
technolog
genet
engin
field
includ
use
tricistron
vector
clone
select
process
base
combin
use
dilut
clone
clone
disc
gener
stabl
cell
line
engin
produc
antiebola
report
stabl
mab
product
cell
line
infrequ
special
literatur
therefor
believ
inform
present
may
use
cell
engin
academia
industri
propos
strategi
simpl
reduc
complex
time
requir
gener
stabl
cell
line
negat
need
costli
equip
materi
cell
line
human
embryon
kidney
cell
use
combin
techniqu
identifi
isol
high
produc
cell
cultur
combin
strategi
consist
convent
antibiot
pressur
use
puromycin
b
use
dilut
clone
protocol
c
disk
clone
techniqu
order
determin
puromycin
gibco
usa
cat
resist
seed
cell
plate
expos
h
differ
puromycin
concentr
rang
ml
stabl
pool
cell
obtain
select
pressur
puromycin
use
select
cycl
ml
week
includ
cultur
expans
stabl
clone
cultur
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
obtain
combin
dilut
clone
use
clone
disc
select
monoclon
cell
high
product
gfp
level
gfp
product
monitor
fluoresc
microscopi
evalu
success
puromycin
select
cultur
growth
transient
cultur
stabl
pool
clonal
cultur
recombin
cell
engin
produc
gp
period
analyz
optic
microscopi
use
axio
imag
microscop
zeiss
germani
equip
led
illumin
system
zeiss
germani
brightfield
fluoresc
micrograph
use
document
progress
express
level
differ
cultur
time
widefield
imag
cm
creat
use
stitch
algorithm
includ
part
microscop
softwar
axioimag
softwar
zeiss
germani
facilit
imag
analysi
quantif
antibodi
product
supernat
cell
cultur
done
use
elisa
assay
specif
human
igg
bethyl
laboratori
tx
usa
cat
standard
curv
rang
ng
ml
antibodi
concentr
calcul
base
standard
curv
assay
conduct
accord
manufactur
instruct
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
also
test
affin
produc
gpebov
cell
cultur
assay
engin
cell
express
gp
protein
ebov
membran
surfac
briefli
transfect
bicistron
vector
contain
inform
tran
membran
express
rfpgp
red
fluoresc
protein
fuse
gp
cell
express
gp
surfac
taken
confluenc
plate
supernat
cell
produc
ad
cell
incub
supernat
discard
adher
cell
wash
three
time
fresh
pb
complex
identifi
ad
polyclon
human
antiigg
antibodi
conjug
fitc
abcam
cambridg
usa
cat
cell
cultur
observ
fluoresc
illumin
optic
microscop
axio
imag
microscop
zeiss
germani
use
set
filter
red
green
reveal
presenc
red
signal
gp
alon
combin
red
green
signal
complex
one
import
bottleneck
process
massiv
product
mab
develop
novel
mab
gener
stabl
clone
time
gener
stabl
cell
long
approxim
month
strategi
base
combin
use
tricistron
vector
also
code
gfp
express
monitor
purpos
b
puromycin
select
use
dilut
clone
clone
disc
method
transfect
select
use
common
reagent
equip
frequent
found
typic
mammalian
cell
cultur
laboratori
use
inexpens
wide
access
equip
reagent
aim
enabl
research
group
current
face
constrain
develop
budget
restrict
timelin
gener
cell
capabl
produc
antiebov
gp
antibodi
gfp
command
uniqu
genet
construct
use
tricistron
vector
altern
produc
three
differ
protein
two
chain
green
fluoresc
protein
gfp
regul
singl
promot
particular
strategi
use
achiev
tricistron
express
schemat
present
figur
light
heavi
chain
link
ire
sequenc
addit
includ
short
linker
ie
heavi
chain
gfp
enabl
express
triad
protein
command
singl
promot
element
intern
ribosom
entri
ire
gene
provid
abil
translat
one
protein
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
may
suffici
applic
relat
protein
qualiti
assess
gfp
express
seen
day
later
suggest
transient
pool
use
purifi
small
quantiti
protein
one
week
transient
express
offer
rapid
way
evalu
potenti
recombin
protein
clinic
test
protein
still
requir
stabl
cultur
largescal
industri
product
state
gener
stabl
cultur
mammalian
cell
produc
monoclon
antibodi
technic
cumbersom
lengthi
studi
relat
develop
stabl
cell
typic
report
timelin
rang
month
involv
multipl
step
pressureselect
new
techniqu
gener
stabl
cell
line
reduc
timelin
gener
involv
use
costli
equip
flow
cytomet
capabl
sort
autom
coloni
pick
ie
clonipix
fl
produc
stabl
cell
pool
less
week
stabl
clone
week
use
method
describ
extend
express
improv
antibodi
product
use
puromycin
kill
lowproduc
cell
select
stabl
pool
clone
highproduc
cell
figur
first
establish
puromycin
kill
curv
rang
concentr
ml
figur
obtain
highest
fraction
transfect
cell
posttreat
viabil
use
concentr
puromycin
ml
use
pressur
strategi
produc
stabl
pool
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
produc
cell
week
cultur
dmem
medium
supplement
bf
ml
puromycin
stabl
pool
cultur
flask
day
concentr
profil
glucos
measur
figur
continu
monitor
glucos
concentr
allow
us
confirm
cell
metabol
activ
suffici
substrat
still
avail
sustain
viabil
product
gfp
express
also
use
report
experi
monitor
viabil
overal
condit
cultur
close
monitor
statu
cultur
visual
inspect
fluoresc
illumin
optic
microscop
figur
determin
concentr
use
elisa
observ
sustain
concentr
level
approxim
mg
igg
l
last
day
stabl
pool
cultur
final
cell
count
cell
volum
ml
figur
refer
valu
impli
specif
cell
product
approxim
pg
cell
day
one
order
magnitud
report
stabl
high
produc
cho
cell
clone
typic
commerci
process
use
stabl
pool
cultur
conduct
dilut
clone
cultur
clone
addit
week
expand
clone
use
clone
disc
singl
clone
grew
new
independ
well
week
scale
cultur
plate
strategi
allow
us
obtain
stabl
clone
approxim
week
stabl
pool
produc
select
highexpress
clone
design
character
select
base
level
fluoresc
emit
cultur
stabl
pool
observ
measur
optic
microscopi
expect
observ
higher
product
stabl
clone
cultur
stabl
pool
select
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
clone
cultur
flask
use
ml
medium
period
day
final
viabl
count
cultur
approxim
cell
determin
maximum
titer
mg
l
day
among
select
clone
best
perform
clone
figur
experi
measur
averag
concentr
valu
approxim
mg
l
among
four
select
clone
mab
titer
report
product
mammalian
cell
rang
microgram
milligram
per
liter
specif
cell
product
observ
four
stabl
clone
cultur
pg
cell
day
rang
valu
obtain
previou
studi
use
similar
complex
cell
engin
strategi
hek
cell
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
titer
product
specif
product
valu
competit
experiment
cultur
still
distant
although
order
magnitud
expect
commerci
scale
product
approxim
pg
cell
day
anticip
applic
standard
optim
protocol
ie
fedbatch
feed
protocol
could
enhanc
product
least
one
order
magnitud
enhanc
possibl
translat
suspend
cultur
instrument
bioreactor
cultur
continu
perfus
cell
adher
cultur
system
ran
pcr
evalu
presenc
gene
transient
pool
stabl
pool
stabl
clone
design
specif
primer
identifi
product
amplif
amplicon
kb
correspond
gene
encod
express
found
gene
associ
product
cultur
figur
also
conduct
western
blot
visual
presenc
full
antibodi
typic
expect
antibodi
signatur
profil
name
two
band
observ
kda
kda
observ
cultur
figur
conduct
addit
vitro
assay
evalu
function
produc
cultur
construct
plasmid
refer
cmvgprfp
drive
express
gp
protein
ebov
fuse
red
fluoresc
protein
rfp
use
plasmid
engin
batch
cell
transient
express
gprfp
cell
surfac
figur
pool
cell
express
gp
surfac
use
visual
evalu
proper
bind
gp
ebola
adher
cultur
gprfp
cell
expos
supernat
cultur
produc
spontan
bind
allow
progress
min
wash
repeat
time
pb
remov
unbound
mab
unit
antiigg
conjug
fitc
ad
visual
revel
presenc
complex
fluoresc
microscopi
figur
observ
expect
merg
red
green
gp
fitc
respect
figur
cultur
stabl
clone
result
suggest
produc
stabl
clone
biolog
function
recogn
specif
bind
gpebov
display
cell
membran
engin
cell
prepared
face
infecti
diseas
key
buffer
spread
epidem
minim
number
human
death
prepared
translat
simpl
concept
access
technolog
resourc
contain
outbreak
efficaci
lesson
learn
ebola
epidem
fast
cost
effect
respons
result
develop
new
diagnost
strategi
detect
ebov
earli
stage
diseas
introduct
efficaci
therapi
current
drug
vaccin
treatment
ebov
alreadi
undergo
fda
approv
process
among
mab
cocktail
recogn
one
promis
treatment
ebov
due
promis
result
vitro
experi
studi
use
anim
model
clinic
trial
howev
import
consider
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
technolog
need
produc
make
avail
suffici
dose
contain
diseas
outbreak
yet
develop
present
costeffici
strategi
could
greatli
shorten
process
develop
stabl
mammalian
cell
clone
capabl
produc
monoclon
antibodi
demonstr
product
antiebov
mab
cell
line
activ
recogn
gp
protein
transient
stabl
pool
stabl
clone
cultur
transient
express
cultur
produc
approxim
mgl
week
use
standard
adher
cell
cultur
techniqu
alon
use
costeffect
select
method
translat
readili
convent
cell
cultur
lab
enabl
develop
stabl
pool
ultim
stabl
clone
therebi
improv
antibodi
product
much
mgl
specif
cell
product
pg
cell
day
four
highproduct
select
clone
specif
product
valu
competit
higher
previous
report
stabl
hek
cell
albeit
still
far
away
product
need
commerci
mab
process
optim
expect
adapt
clone
suspend
cultur
condit
develop
perfus
feed
protocol
two
optim
stage
frequent
result
titer
enhanc
least
two
order
magnitud
methodolog
present
directli
gener
mab
easili
adapt
glycosyl
protein
current
context
pandem
urgenc
abbrevi
process
develop
stabl
clone
evid
ever
respons
capabl
cruelli
challeng
shorten
path
develop
vaccin
neutral
monoclon
antibodi
greatli
benefit
societi
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
